Security
Kiora Pharmaceuticals, Inc. Common Stock · KPRX
KPRXNASDAQCommon stockCurrentCIK 1372514Updated Oct 30, 2026
Name history
EYEGATE PHARMACEUTICALS INC · through Nov 4, 2021
KPRX price & chart
Loading TradingView…
NASDAQ:KPRX on TradingView ↗About the company
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal disease. The Company targets critical pathways underlying retinal diseases using small molecules designed to slow, stop or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential expansion into choroideremia and Stargardt disease. KIO-104 is being developed for macular edema associated with retinal inflammation.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
SCHEDULE 13G - filed by Baselake Partners, LP regarding KIORA PHARMACEUTICALS INC
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding KIORA PHARMACEUTICALS INC
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 29,863,454Source | 38,509,354Source | 23,776,090Source | 31,945,683Source | 40,814,265Source | 21,227,089Source | 34,019,862Source | 42,440,007Source | 24,253,300Source | 36,484,484Source | 13,711,870Source | 18,678,259Source |
| Property, Plant and Equipment, NetUSD | 101,807Source | 62,609Source | 99,637Source | 106,843Source | 63,487Source | 86,815Source | 4,984Source | 12,918Source | 91,672Source | 5,232Source | 8,065Source | 55,177Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,687,100Source | 6,687,100Source | 2,063,100Source | 6,687,100Source | 8,801,350Source | 2,063,100Source | 6,687,100Source | 8,807,600Source | 2,063,100Source | 6,687,100Source | 8,813,850Source | 10,743,164Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,508,899Source | 5,637,019Source | 7,076,533Source | 1,028,324Source | 6,575,394Source | 10,955,359Source | 3,771,024Source | 31,276,330Source | 8,696,570Source | 3,792,322Source | 2,454,684Source | 5,964,556Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,213,226Source | 1,783,472Source | 1,091,385Source | 2,418,022Source | 1,341,297Source | 1,544,253Source | 1,337,604Source | 189,905Source | 1,522,770Source | 601,197Source | — | — |
| Assets, CurrentUSD | 22,693,856Source | 31,652,637Source | 21,262,515Source | 24,737,255Source | 31,830,805Source | 18,682,848Source | 27,107,291Source | 33,481,693Source | 21,748,448Source | 29,706,012Source | 4,738,031Source | 7,680,666Source |
| Prepaid Expense and Other Assets, CurrentUSD | 650,429Source | 470,424Source | 1,127,482Source | 957,095Source | 339,646Source | 1,206,339Source | 941,542Source | 206,671Source | 1,141,804Source | 2,042,487Source | 233,382Source | 343,069Source |
| Operating Lease, Right-of-Use AssetUSD | 318,036Source | 72,637Source | 260,753Source | 349,017Source | 82,322Source | 301,486Source | 152,083Source | 94,298Source | 285,827Source | 57,170Source | 106,890Source | 116,992Source |
| Other Assets, NoncurrentUSD | 58,135Source | 29,851Source | 85,379Source | 61,007Source | 32,122Source | 88,153Source | 64,323Source | 39,414Source | 59,687Source | 24,913Source | 40,767Source | 33,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,452,712Source | 8,479,302Source | 6,919,401Source | 9,818,207Source | 7,712,592Source | 7,292,528Source | 10,319,475Source | 7,535,644Source | 8,126,764Source | 10,724,708Source | 7,602,216Source | 7,270,659Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 4Source | 0Source |
| Common Stock, Value, IssuedUSD | 272,006Source | 267,679Source | 281,943Source | 272,006Source | 267,373Source | 277,606Source | 267,679Source | 262,584Source | 275,289Source | 267,679Source | 77,078Source | 17,986Source |
| Additional Paid in CapitalUSD | 170,083,195Source | 168,996,195Source | 175,544,810Source | 169,828,797Source | 168,825,325Source | 170,521,007Source | 169,304,991Source | 168,429,797Source | 170,314,656Source | 169,156,374Source | 153,192,228Source | 146,035,314Source |
| Retained Earnings (Accumulated Deficit)USD | -147,700,755Source | -139,158,620Source | -158,714,270Source | -147,727,561Source | -135,745,294Source | -156,635,260Source | -145,575,102Source | -133,523,648Source | -154,217,276Source | -143,382,122Source | -146,976,855Source | -134,462,959Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -243,708Source | -75,206Source | -255,798Source | -245,770Source | -245,735Source | -228,796Source | -297,185Source | -264,374Source | -246,137Source | -282,159Source | -182,801Source | -182,741Source |
| Stockholders' Equity Attributable to ParentUSD | 22,410,742Source | 30,030,052Source | 16,856,689Source | 22,127,476Source | 33,101,673Source | 13,934,561Source | 23,700,386Source | 21,515,807Source | 16,126,536Source | 25,759,776Source | 6,109,654Source | 11,407,600Source |
| Liabilities and EquityUSD | 29,863,454Source | 38,509,354Source | 23,776,090Source | 31,945,683Source | 40,814,265Source | 21,227,089Source | 34,019,862Source | 42,440,007Source | 24,253,300Source | 36,484,484Source | 13,711,870Source | 18,678,259Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,580,360Source | 3,527,664Source | 2,370,495Source | 3,185,982Source | 1,655,956Source | 2,798,264Source | 5,274,633Source | 1,592,991Source | 3,631,498Source | 6,008,713Source | 1,633,995Source | 3,272,363Source |
| Operating Lease, Liability, CurrentUSD | 155,926Source | 33,447Source | 172,425Source | 143,327Source | 42,126Source | 178,217Source | 71,554Source | 47,851Source | 164,461Source | 23,355Source | 47,069Source | 105,782Source |
| Accounts Payable, CurrentUSD | 241,471Source | 660,415Source | 216,497Source | 282,537Source | 268,638Source | 594,874Source | 942,492Source | 323,062Source | 1,060,306Source | 415,590Source | 206,260Source | 1,008,262Source |
| Operating Lease, Liability, NoncurrentUSD | 248,239Source | 39,190Source | 160,597Source | 287,079Source | 40,197Source | 195,369Source | 87,470Source | 46,448Source | 203,798Source | 33,815Source | 59,822Source | 0Source |
| Deferred Income Tax Liabilities, NetUSD | 490,690Source | 779,440Source | 102,152Source | 490,690Source | 779,440Source | 102,152Source | 490,690Source | 779,440Source | 102,152Source | 490,690Source | 779,440Source | 689,121Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,153,906Source | 1,714,211Source | 1,981,573Source | 2,540,493Source | 1,345,192Source | 2,025,173Source | 3,522,003Source | 1,222,078Source | 2,406,731Source | 4,588,657Source | 1,380,666Source | 1,835,934Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 102,152Source | 490,690Source | 779,440Source | 689,121Source |
| Short-term InvestmentsUSD | 13,866,546Source | 23,398,016Source | 9,761,994Source | 19,637,812Source | 21,242,671Source | 2,916,701Source | 20,334,831Source | — | 8,392,513Source | 22,999,760Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 10,563Source | 318Source | 24,801Source | 19,205Source | 51,798Source | 41,609Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 209,510Source | 148,616Source | 900,236Source | 656,593Source | 754,944Source | 462,450Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 21,483Source | 736,407Source | 921,573Source | 601,197Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -303,026Source | 1,171,627Source | 1,124,928Source | 226,119Source | -808,016Source | 782,463Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 90,319Source | -113,010Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,161,332Source | -2,704,199Source | -9,961,176Source | 8,559,115Source | -9,556,951Source | -10,428,133Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 5,400,982Source | 2,672,782Source | 14,426,645Source | -22,662,611Source | 0Source | 6,375Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,018Source | 0Source | 110,789Source | 6,256Source | — | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -842Source | 0Source | 265,655Source | 15,498,155Source | 5,966,066Source | 8,620,921Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 2,258,910Source | -21,274Source | 4,904,758Source | 1,337,428Source | -3,554,865Source | -1,885,874Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,513,419Source | 5,641,539Source | 7,081,239Source | 1,032,784Source | 10,960,046Source | 3,775,105Source | 8,701,137Source | 3,796,379Source | 2,458,951Source | 6,013,816Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,423,857Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 20,103Source | 10,143Source | 173,634Source | -57,231Source | 36,020Source | -85,037Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 15,000Source | 25,000Source | 25,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 25,000Source | 5,000Source | 30,000Source | 16,596Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -14,498Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 0Source | -3,760Source | -28,379Source | 4,211Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | -3,859Source | -28,379Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,443,827Source | 1,380,997Source | 1,383,504Source | 1,353,850Source | 1,612,267Source | 1,489,398Source | 5,745,087Source | 5,542,324Source | 4,663,146Source | 8,277,993Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 104,167Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 2,000,000Source | — | — | — | — | 4,624,000Source | 2,008,000Source | 1,904,314Source | — |
| Income Tax Expense (Benefit)USD | — | — | -643,129Source | 0Source | 0Source | -112,057Source | 0Source | 123,006Source | -1,282,149Source | 2,065,005Source | 90,319Source | -113,010Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | 19,960Source | 21,446Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | 225,237Source | — | 277,321Source | 894,002Source | 1,252,849Source | 173,989Source | 56,891Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | — | 2,371Source | 4,519Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 26,806Source | -3,413,326Source | -2,079,010Source | -2,152,459Source | -2,417,984Source | -2,192,980Source | -10,835,154Source | 3,594,733Source | -12,513,896Source | -13,583,610Source |
| Nonoperating Income (Expense)USD | — | — | 178,114Source | 188,911Source | 134,761Source | 131,680Source | 92,212Source | 260,380Source | 713,770Source | 1,149,450Source | 163,319Source | -1,387,097Source |
| Operating ExpensesUSD | — | — | 794,437Source | 3,602,237Source | 2,213,771Source | 2,396,196Source | 2,510,195Source | 2,330,354Source | 12,831,073Source | 11,509,712Source | 12,586,896Source | 12,309,523Source |
| Other Nonoperating Income (Expense)USD | — | — | -23,708Source | -59,929Source | -11,471Source | -93,557Source | -47,127Source | -16,253Source | -160,272Source | 26,073Source | 28,841Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 5,377,719Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 5,406,000Source | 6,212,000Source | 22,408,285Source | 11,637,764Source | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 254,398Source | 171,176Source | 109,310Source | 262,774Source | 209,510Source | 148,616Source | 900,236Source | 656,593Source | 754,944Source | 462,450Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 16,020,000Source | — | — |
| Operating Income (Loss)USD | — | — | -794,437Source | -3,602,237Source | -2,213,771Source | -2,396,196Source | -2,510,195Source | -2,330,354Source | -12,831,073Source | 4,510,288Source | -12,586,896Source | -12,309,523Source |
| Other Nonoperating Income (Expense)USD | — | — | -23,708Source | -59,929Source | -11,471Source | -93,557Source | -47,127Source | -16,253Source | -160,272Source | 26,073Source | 28,841Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -616,323Source | -3,413,326Source | -2,079,010Source | -2,264,516Source | -2,417,984Source | -2,069,974Source | -12,117,303Source | 5,659,738Source | -12,423,577Source | -13,696,620Source |
| Income Tax Expense (Benefit)USD | — | — | -643,129Source | 0Source | 0Source | -112,057Source | 0Source | 123,006Source | -1,282,149Source | 2,065,005Source | 90,319Source | -113,010Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 26,806Source | -3,413,326Source | -2,079,010Source | -2,152,459Source | -2,417,984Source | -2,192,980Source | -10,835,154Source | 3,594,733Source | -12,513,896Source | -13,583,610Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.01Source | -0.81Source | -0.34Source | -0.54Source | -0.58Source | -0.52Source | -2.6Source | 0.93Source | -2.69Source | -18.55Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.01Source | -0.81Source | -0.34Source | -0.54Source | -0.58Source | -0.52Source | -2.64Source | 0.87Source | -2.69Source | -18.55Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,289,853Source | 4,214,950Source | 6,177,679Source | 3,989,042Source | 4,174,802Source | 4,217,007Source | 4,166,692Source | 3,872,644Source | 4,842,067Source | 732,303Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,361,740Source | 4,214,950Source | 6,177,679Source | 3,989,042Source | 4,174,802Source | 4,217,007Source | 4,103,873Source | 4,125,075Source | 4,842,067Source | 732,303Source |
| Interest Expense (non-operating)USD | — | — | — | — | — | — | — | — | 19,960Source | 21,446Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 15,000Source | 25,000Source | 25,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -893,612Source | 2,353,755Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -14,498Source |
| General and Administrative ExpenseUSD | — | — | 1,443,827Source | 1,380,997Source | 1,383,504Source | 1,353,850Source | 1,612,267Source | 1,489,398Source | 5,745,087Source | 5,542,324Source | 4,663,146Source | 8,277,993Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -7,288,452Source | 1,994,760Source | -9,384,178Source | -10,563,302Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 11,132Source | 8,599Source |
| Investment Income, InterestUSD | — | — | — | — | — | 225,237Source | — | 277,321Source | 894,002Source | 1,252,849Source | 173,989Source | 56,891Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | — | — | 2,371Source | 4,519Source | — | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | 26,806Source | -3,413,326Source | -2,079,010Source | -2,152,459Source | -2,417,984Source | -2,192,980Source | -10,835,154Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 178,114Source | 188,911Source | 134,761Source | 131,680Source | 92,212Source | 260,380Source | 713,770Source | 1,149,450Source | 163,319Source | -1,387,097Source |
| Operating ExpensesUSD | — | — | 794,437Source | 3,602,237Source | 2,213,771Source | 2,396,196Source | 2,510,195Source | 2,330,354Source | 12,831,073Source | 11,509,712Source | 12,586,896Source | 12,309,523Source |
| Research and Development ExpenseUSD | — | — | 2,729,891Source | 2,184,991Source | 2,077,116Source | 2,590,489Source | 2,123,725Source | 2,531,887Source | 10,780,397Source | 7,842,207Source | 4,027,037Source | 3,448,925Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 254,398Source | 171,176Source | 109,310Source | 262,774Source | 209,510Source | 148,616Source | 900,236Source | 656,593Source | 754,944Source | 462,450Source |
| Interest Income (Expense), Nonoperating, Net | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-295994
Filing attachments
ex991-pressreleasesenjulic.htm · 8-K · 2026-10-29
Exhibit 99.1 Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan • The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls. • No therapeutics exist today to treat patients that experience CRAO vision loss. • Kiora pl…
Read attachment ↗ex992-companypresentatio.htm · 8-K · 2026-10-29
Kiora Pharmaceuticals, Inc. Q4 2026 | Corporate Overview 2 This presentation is provided for informational purposes only. Some of the material and statements in this presentation are "forward-looking" statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements concerning Kiora's planned development and potential commercialization of KIO-401; the anticipated timing, design, initiation, co…
Read attachment ↗ex991-pressreleasekeithlan.htm · 8-K · 2026-09-08
EX-99.1 3 ex991-pressreleasekeithlan.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora’s pipeline and new asset opportunities ENCINITAS, CA -- September 8, 2026 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the…
Read attachment ↗ex991-pressreleaseckdaugus.htm · 8-K · 2026-08-19
EX-99.1 3 ex991-pressreleaseckdaugus.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation ENCINITAS, Calif., August 19, 2026 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora”) today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporatio…
Read attachment ↗ex991-pressreleasejune3020.htm · 8-K · 2026-08-07
EX-99.1 2 ex991-pressreleasejune3020.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update ENCINITAS, Calif. - August 7, 2026 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Rec…
Read attachment ↗ex991-pressreleasejune1820.htm · 8-K · 2026-06-18
EX-99.1 2 ex991-pressreleasejune1820.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity The findings were reported at The Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026 KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora’s ongoin…
Read attachment ↗